search icon
maze-img

Maze Therapeutics, Inc. Common Stock, Common Stock

MAZE

NMQ

$10.405

-$1.77

(-14.54%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$445.42M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
59.71K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.71 L
$17 H
$10.405

About Maze Therapeutics, Inc. Common Stock, Common Stock

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameMAZESectorS&P500
1-Week Return19.67%1.39%1.18%
1-Month Return38.45%-4.97%6.44%
3-Month Return-0.49%-11.13%-0.73%
6-Month Return-23.94%-10.21%-2.01%

Financials

Dec '22Dec '23Dec '24
Total Revenue--167.50M[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue---[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit--167.50M[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin--100.00%[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses111.03M98.55M109.91M[{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":88.76,"profit":true},{"date":"2024-12-31","value":99,"profit":true}]
Operating Income(111.03M)(98.55M)57.59M[{"date":"2022-12-31","value":-192.8,"profit":false},{"date":"2023-12-31","value":-171.14,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(1.89M)102.00K471.00K[{"date":"2022-12-31","value":-400.42,"profit":false},{"date":"2023-12-31","value":21.66,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(114.94M)(100.42M)53.40M[{"date":"2022-12-31","value":-215.23,"profit":false},{"date":"2023-12-31","value":-188.03,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income Taxes--1.17M[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes--52.23M[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income From Continuous Operations(114.94M)(100.42M)52.23M[{"date":"2022-12-31","value":-220.06,"profit":false},{"date":"2023-12-31","value":-192.25,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income From Discontinued Operations---[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(114.94M)(100.42M)52.23M[{"date":"2022-12-31","value":-220.06,"profit":false},{"date":"2023-12-31","value":-192.25,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
EPS (Diluted)---[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MAZE
Cash Ratio 15.81
Current Ratio 16.10

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MAZE
ROA (LTM) 0.00%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MAZE
Debt Ratio Lower is generally better. Negative is bad. 0.12
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.88

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MAZE
Trailing PE NM
Forward PE NM
P/S (TTM) 3.14
P/B 0.00
Price/FCF NM
EV/R 2.72
EV/Ebitda 6.71

FAQs

What is Maze Therapeutics, Inc. Common Stock share price today?

Maze Therapeutics, Inc. Common Stock (MAZE) share price today is $10.405

Can Indians buy Maze Therapeutics, Inc. Common Stock shares?

Yes, Indians can buy shares of Maze Therapeutics, Inc. Common Stock (MAZE) on Vested. To buy Maze Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MAZE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Maze Therapeutics, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of Maze Therapeutics, Inc. Common Stock (MAZE) via the Vested app. You can start investing in Maze Therapeutics, Inc. Common Stock (MAZE) with a minimum investment of $1.

How to invest in Maze Therapeutics, Inc. Common Stock shares from India?

You can invest in shares of Maze Therapeutics, Inc. Common Stock (MAZE) via Vested in three simple steps:

  • Click on Sign Up or Invest in MAZE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Maze Therapeutics, Inc. Common Stock shares
What is Maze Therapeutics, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of Maze Therapeutics, Inc. Common Stock (MAZE) is $17. The 52-week low price of Maze Therapeutics, Inc. Common Stock (MAZE) is $6.71.

What is Maze Therapeutics, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Maze Therapeutics, Inc. Common Stock (MAZE) is 0.00

What is the Market Cap of Maze Therapeutics, Inc. Common Stock?

The market capitalization of Maze Therapeutics, Inc. Common Stock (MAZE) is $445.42M

What is Maze Therapeutics, Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of Maze Therapeutics, Inc. Common Stock is MAZE

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top